Vitamin D3 supplementation boosts fluoropyrimidine efficacy in metastatic CRC, increasing ORR to 63.3% and prolonging PFS.
Background
Metastatic colorectal cancer (CRC) remains a significant challenge, with fluoropyrimidine regimens forming the backbone of systemic chemotherapy. Despite these treatments, patient outcomes are often suboptimal, highlighting a critical need for adjunct therapies that can enhance efficacy and improve survival. Vitamin D3 has emerged as a potential modulator of cancer pathways, particularly influencing angiogenesis and cellular proliferation, which are key drivers of CRC progression and resistance to chemotherapy. Understanding how vitamin D3 interacts with these mechanisms could unlock a safe, low-cost strategy to improve patient prognosis.
Study Design
This study evaluated metastatic colorectal cancer (CRC) patients receiving fluoropyrimidine-based chemotherapy. Patients were divided into a group receiving vitamin D3 supplementation and a control group without supplementation. Serum vitamin D3 levels, and the expression of vascular endothelial growth factor (VEGF) and cellular myelocytomatosis (C-Myc) were measured at baseline and after two months of therapy. Primary clinical endpoints included overall response rate (ORR), progression-free survival (PFS), and overall survival (OS) to assess the clinical benefits of vitamin D3 addition.
Results
Patients receiving vitamin D3 supplementation demonstrated a significant rise in median vitamin D3 levels after two months, increasing from 8 ng/mL (IQR 6-14) to 13.5 ng/mL (IQR 8-16.3), with a median change (Δ) of +5.5 ng/mL (IQR 3-8) (Wilcoxon p<0.001). Conversely, the control group experienced a decline in median vitamin D3 levels from 11 ng/mL (IQR 8-14.3) to 9 ng/mL (IQR 8-16.3), with a Δ of -2 ng/mL (IQR -4 to +1) (Wilcoxon p=0.01). Supplementation was also associated with greater downregulation of VEGF and C-Myc expression (p<0.05).
The overall response rate was significantly higher in the vitamin D3 group (63.3% vs. 25.8%;
p<0.01), and medianPFSwas notably prolonged (9.1 months vs. 6.5 months;p=0.028).
Key Findings
- Vitamin D3 supplementation significantly increased median serum vitamin D3 levels by +5.5 ng/mL after two months (
p<0.001). - Supplementation led to greater downregulation of
VEGFandC-Mycexpression (p<0.05). - Overall response rate (ORR) was higher in the vitamin D3 group (63.3% vs. 25.8%;
p<0.01). - Median progression-free survival (PFS) was significantly prolonged (9.1 months vs. 6.5 months;
p=0.028).
Why It Matters
This study provides compelling evidence that vitamin D3 supplementation can significantly enhance the efficacy of fluoropyrimidine chemotherapy in metastatic CRC patients, offering a practical, low-cost adjunct. The observed improvements in ORR and PFS, coupled with the modulation of VEGF and C-Myc pathways, suggest a direct mechanistic benefit. For clinicians, this indicates that optimizing vitamin D levels could be a simple yet impactful strategy to improve patient outcomes. While specific dosing protocols for vitamin D3 were not detailed, the findings support the integration of vitamin D status monitoring and supplementation into standard CRC management, potentially extending survival and improving response rates without adding significant toxicity.
vitamin-d3
colorectal-cancer
metastatic-crc
chemotherapy
fluoropyrimidine
angiogenesis